Literature DB >> 26707950

Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Lei Li1,2, Nikolai Petrovsky1,2.   

Abstract

In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this problem, including novel plasmid vectors and codon optimization to enhance antigen expression, new gene transfection systems or electroporation to increase delivery efficiency, protein or live virus vector boosting regimens to maximise immune stimulation, and formulation of DNA vaccines with traditional or molecular adjuvants. Better understanding of the mechanisms of action of DNA vaccines has also enabled better use of the intrinsic host response to DNA to improve vaccine immunogenicity. This review summarizes recent advances in DNA vaccine technologies and related intracellular events and how these might impact on future directions of DNA vaccine development.

Entities:  

Keywords:  DNA vaccine; immunogenicity; molecular adjuvant; plasmid; vaccine delivery

Mesh:

Substances:

Year:  2015        PMID: 26707950      PMCID: PMC4955855          DOI: 10.1586/14760584.2016.1124762

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  176 in total

1.  Short noncoding DNA fragment improve efficiencies of in vivo electroporation-mediated gene transfer.

Authors:  Jinliang Peng; Yonggang Zhao; Junhua Mai; Wei Guo; Yuhong Xu
Journal:  J Gene Med       Date:  2012 Sep-Oct       Impact factor: 4.565

2.  Targeting DNA vaccines to myeloid cells using a small peptide.

Authors:  Chunting Ye; Jang Gi Choi; Sojan Abraham; Premlata Shankar; N Manjunath
Journal:  Eur J Immunol       Date:  2014-11-02       Impact factor: 5.532

3.  RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency.

Authors:  S-T Wang; C-C Chang; M-C Yen; C-F Tu; C-L Chu; Y-T Peng; D-Y Chen; J-L Lan; C-C Lin
Journal:  Gene Ther       Date:  2010-11-25       Impact factor: 5.250

4.  Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium.

Authors:  M Uchijima; A Yoshida; T Nagata; Y Koide
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

5.  The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.

Authors:  Pallab Pradhan; Hong Qin; Jardin A Leleux; Dongho Gwak; Ippei Sakamaki; Larry W Kwak; Krishnendu Roy
Journal:  Biomaterials       Date:  2014-04-08       Impact factor: 12.479

6.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Authors:  Spyros A Kalams; Scott D Parker; Marnie Elizaga; Barbara Metch; Srilatha Edupuganti; John Hural; Stephen De Rosa; Donald K Carter; Kyle Rybczyk; Ian Frank; Jonathan Fuchs; Beryl Koblin; Denny H Kim; Patrice Joseph; Michael C Keefer; Lindsey R Baden; John Eldridge; Jean Boyer; Adam Sherwat; Massimo Cardinali; Mary Allen; Michael Pensiero; Chris Butler; Amir S Khan; Jian Yan; Niranjan Y Sardesai; James G Kublin; David B Weiner
Journal:  J Infect Dis       Date:  2013-07-08       Impact factor: 5.226

7.  Short noncoding DNA fragments improve the immune potency of electroporation-mediated HBV DNA vaccination.

Authors:  J Peng; S Shi; Z Yang; Q Ding; W Hai; H Tang; Y Yang; J R Bernstein; P Peyda; Y Xu
Journal:  Gene Ther       Date:  2014-05-15       Impact factor: 5.250

Review 8.  Targeting skin dendritic cells to improve intradermal vaccination.

Authors:  N Romani; V Flacher; C H Tripp; F Sparber; S Ebner; P Stoitzner
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

9.  The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response.

Authors:  Kislay Parvatiyar; Zhiqiang Zhang; Rosane M Teles; Songying Ouyang; Yan Jiang; Shankar S Iyer; Shivam A Zaver; Mirjam Schenk; Shang Zeng; Wenwan Zhong; Zhi-Jie Liu; Robert L Modlin; Yong-jun Liu; Genhong Cheng
Journal:  Nat Immunol       Date:  2012-11-11       Impact factor: 25.606

10.  Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity.

Authors:  M Bivas-Benita; G O Gillard; L Bar; K A White; R J Webby; A-H Hovav; N L Letvin
Journal:  Mucosal Immunol       Date:  2012-07-18       Impact factor: 7.313

View more
  65 in total

1.  Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.

Authors:  Ingrid Karlsson; Marie Borggren; Jens Nielsen; Dennis Christensen; Jim Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2017-06-14       Impact factor: 3.452

2.  Cloning of ompA gene from Acinetobacter baumannii into the eukaryotic expression vector pBudCE4.1 as DNA vaccine.

Authors:  Hossein Ansari; Abbas Doosti; Mohammad Kargar; Mahdi Bijanzadeh; Mojtaba Jaafarinia
Journal:  Indian J Microbiol       Date:  2018-02-09       Impact factor: 2.461

3.  Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.

Authors:  Zhidong Hu; Weimin Jiang; Ling Gu; Dan Qiao; Tsugumine Shu; Douglas B Lowrie; Shui-Hua Lu; Xiao-Yong Fan
Journal:  J Mol Med (Berl)       Date:  2019-11-30       Impact factor: 4.599

4.  Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.

Authors:  Mariane Melo; Ely Porter; Yuan Zhang; Murillo Silva; Na Li; Brian Dobosh; Alessia Liguori; Pat Skog; Elise Landais; Sergey Menis; Devin Sok; David Nemazee; William R Schief; Ron Weiss; Darrell J Irvine
Journal:  Mol Ther       Date:  2019-08-19       Impact factor: 11.454

5.  The concurrent effects of azurin and Mammaglobin-A genes in inhibition of breast cancer progression and immune system stimulation in cancerous BALB/c mice.

Authors:  Payam Ghasemi-Dehkordi; Abbas Doosti; Mohammad-Saeid Jami
Journal:  3 Biotech       Date:  2019-06-18       Impact factor: 2.406

6.  Development of Cancer Immunotherapies.

Authors:  Diana C DeLucia; John K Lee
Journal:  Cancer Treat Res       Date:  2022

Review 7.  Oxidative stress implications for therapeutic vaccine development against Chagas disease.

Authors:  Subhadip Choudhuri; Lizette Rios; Juan Carlos Vázquez-Chagoyán; Nisha Jain Garg
Journal:  Expert Rev Vaccines       Date:  2021-08-30       Impact factor: 5.217

Review 8.  A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Authors:  Don Jeffrey Diamond; Corinna La Rosa; Flavia Chiuppesi; Heidi Contreras; Sanjeet Dadwal; Felix Wussow; Supriya Bautista; Ryotaro Nakamura; John A Zaia
Journal:  Expert Rev Vaccines       Date:  2018-10-03       Impact factor: 5.217

Review 9.  Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics.

Authors:  Xiao Tan; Justin H Letendre; James J Collins; Wilson W Wong
Journal:  Cell       Date:  2021-02-10       Impact factor: 41.582

Review 10.  COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.

Authors:  Zhi-Peng Yan; Ming Yang; Ching-Lung Lai
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.